Sign In
Buy BTX
$8.05
+0.150 (+1.90%)
At Close: Jul 31, 2026
These 3 Big Dividends Just Got Cut. They're Safer Than Ever
12:20pm, Tuesday, 24'th Jun 2025
If you invest for long enough, you may hear a skeptic of high-yield investments—such as 8%+ yielding closed-end funds (CEFs)—say something like:
BlackRock Technology and Private Equity Term Trust (BTX) Commences Tender Offer for up to 50% of outstanding common shares
04:31pm, Monday, 09'th Jun 2025
NEW YORK--(BUSINESS WIRE)---- $BTX--BlackRock Technology and Private Equity Term Trust (NYSE: BTX) (the “Fund”) announced today the commencement, expiration and pricing dates of the previously ann
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
04:31pm, Friday, 30'th May 2025
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYS
BTX: Why The June Tender Offer Keeps This A 'Buy'
01:44am, Thursday, 29'th May 2025
I reiterate my Buy rating on BTX, due to the upcoming June tender offer at 99.5% of NAV, providing a low-risk exit opportunity. The fund's discount to NAV has narrowed, but the tender offer could unlo
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
07:40pm, Wednesday, 30'th Apr 2025
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYS
BlackRock Announces Shareholder Approval of Strategy Changes to the BlackRock Technology and Private Equity Term Trust (BTX)
04:30pm, Thursday, 17'th Apr 2025
NEW YORK--(BUSINESS WIRE)---- $BTX--BlackRock Advisors, LLC announced today the results of the Special Shareholder Meeting of the BlackRock Technology and Private Equity Term Trust (NYSE: BTX) (the �
CEF Weekly Review: BlackRock Resets Its Tender Offers
02:00pm, Sunday, 13'th Apr 2025
We review the CEF market valuation and performance through the first week of April and highlight recent market action. Nearly all CEF sectors were down; Munis and Agencies saw gains due to the sharp d
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
05:35pm, Monday, 31'st Mar 2025
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYS
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
04:59pm, Friday, 28'th Feb 2025
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYS
Latest Business Market Insights added report on Europe Stem Cell Therapy Market research study by Market Digits offers detailed product outlook and elaborates market review till 2027. The market Study is segmented by key regions that is accelerating the marketization.
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
08:00am, Thursday, 02'nd Dec 2021
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
04:15pm, Thursday, 14'th Oct 2021
Ticker Symbol to Remain “BTX” Ticker Symbol to Remain “BTX”
Brooklyn ImmunoTherapeutics Reports Inducement Grants
04:30pm, Thursday, 23'rd Sep 2021
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene e
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
10:07am, Wednesday, 22'nd Sep 2021
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
08:30am, Tuesday, 21'st Sep 2021
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene e
